Company: CI
Filing Date: 2025-03-14
Form Type: DEF 14A
Source: 0001739940-25-000015
Chunk: 111

Company: Cigna Group
Filing Date: 2025-03-14
Form: DEF 14A
Chunk 111
---
 Act, Rule 10D-1 of the Exchange Act, and NYSE Rule 303A.14, while keeping its pre-existing clawback policy in place.

• Annual Meeting Q&A : The Cigna Group Annual Meeting of Shareholders format allows for meaningful shareholder participation through a general question and answer session.

| 108 |     | The Cigna Group| 2025 Notice of Annual Meeting of Shareholders and Proxy Statement |

| SHAREHOLDER PROPOSALS |

In addition to these policies and practices, the Board and management have been proactive in their engagement with shareholders on Company performance, governance, executive compensation, and corporate responsibility topics. Our Corporate Secretary, Senior Vice President of Investor Relations, and representatives of The Cigna Group Office of the Corporate Secretary, Executive Compensation, and Environmental, Social and Governance teams conduct meetings to update investors and regularly convey feedback from those meetings to the Chairman of the Board, our Lead Independent Director, and other members of the Board and management. Since the filing of the 2024 proxy statement, The Cigna Group invited holders of approximately 70% of our outstanding stock to engage with us on governance-related topics and engaged on governance-related topics with holders of approximately 30% of our outstanding stock.

Our engagement with shareholders continues to influence our policies and practices. As disclosed in “Corporate Governance Matters – Shareholder Engagement” we have implemented several governance enhancements in recent years for which shareholders have expressed support in our engagement discussions, including our adoption of a policy regarding inclusion of candidates from underrepresented backgrounds in director searches, the adoption of amendments to our By-Laws to provide for a proxy access right and the shareholder right to call a special meeting, and the elimination of supermajority voting provisions in our governing documents.

#### Summary
After careful consideration, our Board determined that the implementation of this proposal is not in the best interests of The Cigna Group or our shareholders and is unnecessary given the current special meeting right that strikes the appropriate balance between protecting the rights of our long-term shareholders and mitigating risk of abuse. Our Board believes that the Company’s strong corporate governance practices, including its commitment to ongoing dialogue with its shareholders, our Board’s track record of responsiveness, and the current special meeting right, provide shareholders with the ability to raise important matters with our Board and management without the potential expense and risk associated with the proposal to abolish the one-year holding period requirement.

Accordingly, our Board unanimously recommends that shareholders vote AGAINST this proposal .

| The Cigna Group| 2025 Notice of